Watch for Oteseconazole, a New Rx for Vaginal Yeast Infections

September 2022

New Rx oteseconazole (Vivjoa), the first med approved for recurrent vaginal yeast infections, may pop up on home med lists.

This oral med is only for patients with 3 or more vaginal yeast infections per year who are postmenopausal or permanently infertile.

That’s because oteseconazole is teratogenic in animals...and can stay in the body for up to 2 YEARS. So for now, it shouldn’t be used in ANY patient of childbearing potential.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Safety Ensure Safety With IV Potassium Chloride 500 mEq Bags
Compounding Prevent Particles in Sterile Preps
Pharmacy Technicians Set Yourself Up for Success When Interviewing for New Tech Roles
Med Safety Keep Med Concentrations Straight
Infectious Diseases Help Stop Spread of Monkeypox Misinformation
Substance Use Disorder Shortages Will Affect Alcohol Withdrawal Treatment
Heart Failure Avoid Mishaps With SGLT2 Inhibitors
Influenza Know What’s New With Flu Vaccines for 2022-2023
New Drugs Watch for Oteseconazole, a New Rx for Vaginal Yeast Infections

Watch for Oteseconazole, a New Rx for Vaginal Yeast Infections

Practical advice for a better career, with unlimited access to CE

Table of Contents